Ahdab et al, 2020. Journal of Clinical Medicine.
- A double-blind and sham-controlled RCT that evaluated the efficacy of tDCS in patients with migraine.
- Forty-two patients (N = 42) received either 3 days of daily cathodal tDCS over the occipital cortex (O1/O2), or sham tDCS.
- 2 mA cathodal tDCS was given for 20 minutes per session, delivered with the Sooma tDCS device.
- Results showed that active tDCS led to reductions in number of headache days, average daily pill consumption, and pain intensity.
- The beneficial effects lasted for over two weeks.
- The treatment was concluded to be effective, safe, and well-tolerated.